Latest News
All Times Eastern
- Bond yields steady before payrolls after week of big price gains
- These analysts say the office and apartment building worries after NYCB are like Groundhog Day — but do concede one issue
- Car loaded with gas in Kenya explodes and sets off inferno that injures more than 270, kills at least 33
- Barron's Energy Stocks Have Struggled. Why They Shine as Dividend Payers.
- Barron's Philip Morris Stock Stands to Get a Boost From Earnings
- Barron's Brazil Is Having a Great Time. 5 Stocks to Play.
- Barron's Boeing’s Troubles Aren’t Going Away. How to Profit From Its Problems.
- Barron's The 6% Commission for Home Sales Is Under Attack. Inside the Fight to Keep It Alive.
- Prosecutors weigh perjury charge for ex-Trump CFO Allen Weisselberg over civil fraud trial testimony
- Shares of China’s Landsea Green rise on plan to buy Texas homebuilder for $185 million
to be replaced
PepGen Inc.
PEPGUS
$
0.86
6.94%
Premarket
$
13.25
Before Hours Volume:
13
| Close | Chg | Chg % |
|---|---|---|
| $12.39 | 2.36 | 23.53% |
Volume: 1.21M
65 Day Avg: 103.82K
10.03
Day Range
12.99
3.72
52 Week Range
20.00
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
PEPG Overview
Key Data
- Open $10.04
- Day Range 10.03 - 12.99
- 52 Week Range 3.72 - 20.00
- Market Cap $238.85M
- Shares Outstanding 23.81M
- Public Float 18.39M
- Beta 1.13
- Rev. per Employee N/A
- P/E Ratio N/A
- EPS -$3.12
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 282.18K 01/12/24
- % of Float Shorted 1.53%
- Average Volume 103.82K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 5
Full Ratings
Recent News
PepGen started at outperform with $17 stock price target at Wedbush
Activist Investing Covetrus and PepGen Stock See Action From Activist Investors
12 Health Care Stocks Moving In Tuesday's Intraday Session
on Benzinga.com
Wedbush Keeps Their Buy Rating on PepGen Inc. (PEPG)
on TipRanks.com
PepGen: Q3 Earnings Insights
on Benzinga.com
H.C. Wainwright Reaffirms Their Buy Rating on PepGen Inc. (PEPG)
on TipRanks.com
PepGen Director Awarded $85K Worth of Stock Options
on Benzinga.com
PepGen Director Awarded $114K Worth of Stock Options
on Benzinga.com
The Latest Analyst Ratings for PepGen
on Benzinga.com
Insider Sell: President and CEO James Mcarthur Sells 2,381 Shares of PepGen Inc (PEPG)
Insider Sell: President and CEO James Mcarthur Sells 2,381 Shares of PepGen Inc (PEPG)
on GuruFocus.com
12 Health Care Stocks Moving In Friday's Intraday Session
on Benzinga.com
SAIC, HealthEquity And 3 Stocks To Watch Heading Into Monday
on Benzinga.com
PepGen Inc.
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.